| Filed On | Filing |
|---|---|
| 27 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 05 Oct 2026 |
Form 4: Arbet-Engels Christophe, Chief Medical Officer
Received 37,500 shares by exercise or conversion · Gave up 12,679 shares to cover exercise price or tax ($35K) |
| 05 Oct 2026 |
Form 4: Weaver Gregory L, Chief Financial Officer
Received 14,475 shares by exercise or conversion · Gave up 4,379 shares to cover exercise price or tax ($12.1K) |
| 02 Oct 2026 |
Form 4: Menziuso Richard Thomas, Principal Accounting Officer
Granted 84,546 Stock Options (option to buy) · Granted 36,234 Restricted Stock Units |
| 02 Oct 2026 |
Form 3: Menziuso Richard Thomas, Principal Accounting Officer
No securities owned |
| 29 Sep 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
On September 24, 2026, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Richard Menziuso as the Company’s Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2... |
| 17 Sep 2026 |
Form 4: Richardson Linda M, Chief Commercial Officer
Received 24,000 shares by exercise or conversion · Gave up 6,826 shares to cover exercise price or tax ($22.1K) |
| 13 Aug 2026 |
Form 4: Durso Jerome Benedict, Director
Bought 15,000 shares ($44.3K) |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 03 Aug 2026 |
Form 4: Weaver Gregory L, Chief Financial Officer
Received 1,753 shares as a grant or award ($4.23K) |
| 03 Aug 2026 |
Form 4: Roberts M Scot, Chief Scientific Officer
Received 875 shares as a grant or award ($2.11K) |
| 28 Jul 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 16 Jun 2026 | 8-K: Other Events |
| 15 May 2026 | SCHEDULE 13G/A |
| 13 May 2026 | S-8 |
| 13 May 2026 | 10-Q |
| 13 May 2026 | 8-K: Results of Operations and Financial Condition |
| 12 May 2026 | SCHEDULE 13G |
| 01 May 2026 | SCHEDULE 13G |
Loading...
